on Aspire Biopharma, Inc. (NASDAQ:PWUP)
Aspire Biopharma Announces Nasdaq Listing Following Merger
Aspire Biopharma Holdings, Inc. has completed its business combination with PowerUp Acquisition Corp., establishing a presence on the Nasdaq under the ticker "ASBP" starting February 20, 2025. This move aims to enhance Aspire’s access to capital and foster expansion of its innovative product pipeline, which addresses key medical needs. The company is focused on breakthrough drugs like a fast-acting aspirin for cardiac emergencies and a novel Viagra/Cialis combo. Aspire leverages its unique sublingual delivery system for rapid absorption, bypassing the gastrointestinal tract.
Funds from the merger, totaling around $3.8 million, are set to advance Aspire's strategic growth, enable new partnerships, and drive trials for its leading aspirin product, a candidate for FDA fast-track approval. Leadership remains stable with Kraig Higginson as CEO, continuing to steer the company towards significant developments in biopharma technology.
R. H.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Aspire Biopharma, Inc. news